Catabasis Pharmaceuticals, Inc.

Sirtris Pharmaceuticals, Inc.

Glaxosmithkline LLC

Other

Biogen Idec Ma Inc.

Biogen, Incorporated

Biogen Idec, Inc.

Milne, Jill C.

Ting, Amal

Jirousek, Michael R.

Vu, Chi B.

Bemis, Jean E.

Chi B Vu

Jean E Bemis

Jill C Milne

Michael R Jirousek

Jeremy S Disch

Pui Yee Ng

Joseph J Nunes

Robert B Perni

Roger Xie

Christopher Oalmann

Amal Ting

Charles A Blum

David M Armistead

Thomas Salzmann

Ko-Chung Lin

Jesse J Smith

Walter Lunsmann

Russell Colyn Petter

Gnanasambandam Kumaravel

Michael V Milburn

Brian H White

Rebecca L Casaubon

Lauren McPherson

Mohammed Mahmood Ahmed

Allison Wensley

Radha Narayan

Stephanic K Springer

Karl D Normington

Michael Jirousek

Brian White

Walter Joseph Lunsmann

Stephanie K Springer

Lauren Mcpherson

The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNGlE), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)&#x2014;N-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5Z, 8Z, 11Z, 14Z, 17Z)&#x2014;N-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide.

Fatty acid cysteamine conjugates and their use as activators of autophagy

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.

Fatty acid niacin conjugates and their uses

The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.

Fatty acid acylated salicylates and their uses

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Bicyclic pyridines and analogs as sirtuin modulators

The invention relates to niacin conjugated fatty acid mixtures; compositions comprising an effective amount of a niacin conjugated fatty acid mixture; and methods for treating or preventing an metabolic disorder comprising the administration of as effective amount of a niacin conjugated fatty acid mixture.

Niacin conjugated fatty acid mixtures and their uses

Quinazolinone, quinolone and related analogs as sirtuin modulators

The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.

Fatty acid fumarate derivatives and their uses

The invention relates to fatty acid COX inhibitor derivatives; compositions comprising an effective amount of a fatty acid COX inhibitor derivative; and methods for treating or preventing a metabolic, autoimmune, inflammatory, or neurodegenerative disorder comprising the administration of an effective amount of a fatty acid COX inhibitor derivative.

Fatty acid COX inhibitor derivatives and their uses

The invention relates to fatty acid guanidine or salicylate guanidine derivatives; compositions comprising an effective amount of a fatty acid guanidine or salicylate guanidine derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid guanidine or salicylate guanidine derivative.

Fatty acid guanidine and salicylate guanidine derivatives and their uses

The invention relates to fatty acid statin conjugates and fatty acid FXR agonist conjugates; compositions comprising an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate.

Fatty acid conjugates of statin and FXR agonists; compositions and method of uses

Growing community of inventors

Arlington, MA, United States of America

Chi B Vu